SHAREHOLDER ALERT: CTAS and CORV: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / January 24, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Cintas Corporation (CTAS)
Class Period: March 6, 2017 - November 13, 2019
Deadline: February 10, 2020
For more info: www.bgandg.com/ctas

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Cintas never tracked legacy margins following the G&K acquisition; (2) the Company has systematically provided guidance with which it would outperform (a "Beat and Raise" scheme); (3) undisclosed to the investing public, the Company has breached the law multiple times; (4) as a result of publicly known and undisclosed breaches of law, the Company's Credit Agreement may be jeopardized; and (5) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Correvio Pharma Corp. (CORV)
Class Period: October 23, 2018 - December 5, 2019
Deadline: February 10, 2020
For more info: www.bgandg.com/corv

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting the Resubmitted New Drug Application ("NDA") for Brinavess did not minimize the significant health and safety issues observed in connection with the drug's original NDA; (2) the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) as a result, Correvio's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View source version on accesswire.com:
https://www.accesswire.com/571123/SHAREHOLDER-ALERT-CTAS-and-CORV-Bronstein-Gewirtz-Grossman-LLC-Reminds-Shareholders-With-Losses-Exceeding-100K-of-Class-Action-Deadlines